您现在的位置: 首页> 研究主题> 辅助生殖技术(ART)

辅助生殖技术(ART)

辅助生殖技术(ART)的相关文献在2007年到2021年内共计71篇,主要集中在妇产科学、一般理论、基础医学 等领域,其中期刊论文71篇、专利文献425372篇;相关期刊6种,包括生命科学研究、中国性科学、医学与哲学等; 辅助生殖技术(ART)的相关文献由226位作者贡献,包括刘嘉茵、涂玲、乔杰等。

辅助生殖技术(ART)—发文量

期刊论文>

论文:71 占比:0.02%

专利文献>

论文:425372 占比:99.98%

总计:425443篇

辅助生殖技术(ART)—发文趋势图

辅助生殖技术(ART)

-研究学者

  • 刘嘉茵
  • 涂玲
  • 乔杰
  • 卢光琇
  • 孙莹璞
  • 王晓红
  • 郭翔宇
  • 卢光磅
  • 吴彤华
  • 孙赟
  • 期刊论文
  • 专利文献

搜索

排序:

年份

    • 金美玲
    • 摘要: 目的:探讨综合护理干预对辅助生殖技术(ART)治疗的不孕症患者受孕情况的影响。方法:选取我院不孕症 患者40例作为本次研究观察对象,按照患者个人意愿进行分组,分为对照组(n =20)行ART治疗常规护理干预,另 一组为观察组(n =20)行ART治疗综合护理干预,观察两组患者不同护理干预下对妊娠率及护理满意度分析。结果: 行综合护理干预下的观察组,妊娠率高于对照组,与之差异显著(P <0.05),且该组患者护理满意度较高,差异明 显(P <0.05)。结论:为不孕症患者进行ART治疗期间,介入综合护理干预,能提高患者妊娠率及护理满意度,值 得临床借鉴。
    • 李楠; 林忠
    • 摘要: 研究显示,白血病抑制因子(leukemia inhibitory factor,LIF)、白介素-1(interleukin-1,IL-1)、胰岛素样生长因子(insulin-like growth factors,IGF)、前列腺素(prostaglandin,PG)、基质金属蛋白酶(matrixmetalloproteinases,MMPs)和组织金属蛋白酶抑制剂(tissue inhibitor of matrix metalloproteinases,TIMPs)等可作为子宫内膜容受性的分子标志物.本文主要对评估子宫内膜容受性的分子标志物进行综述,以期更好地评估子宫内膜的容受性,进一步提高临床妊娠率.
    • 吕爱霞; 常飞; 孙小燕; 任杉杉; 莫少康; 王玲
    • 摘要: Objective To investigate whether Connexin 37 (Cx37) rs1764391 polymorphism could predict ovarian stimulation and reproductive outcomes in patients with polycystic ovary syndrome (PCOS). Methods A total of 98 PCOS patients undergoing assisted reproductive technology (ART) were included in the present study. The genotype of rs1764391 was detected using Taqman PCR method. Then the relationship of rs1764391 polymorphism with controlled ovarian hyperstimulation, reproductive outcomes were assessed. Results The frequencies of TT genotype (18.4%) and T allele (31.6%) were significantly higher in patients with PCOS (9.6%, P=0.03; 22.3%, P=0.04). LH concentration, estradiol level and the number of retrieved oocytes were significantly higher in PCOS patients with TT genotype when compared with other genotypes. Besides, embryo implantation rate (27.5%) and clinical pregnancy rate (30.7%) were significantly lower in PCOS patients with TT genotype than in patients with CC and CT genotypes (47.2%, 52.3%, P=0.02; 57.4%, 69.6%, P=0.03). Similarly, the low rate of clinical pregnancy was observed in PCOS patients with T allele (45.1%) than in patients with C genotype (66.8%, P=0.04). Conclusion In PCOS patients, Cx37 rs1764391 polymorphisms were significantly associated with reproductive outcomes.%目的 分析连接蛋白37(Cx37)rs1764391基因多态性在多囊卵巢综合征(PCOS)患者中对控制性超促排卵的反应性及其妊娠结局的影响.方法 选择经辅助生殖技术(ART)治疗的98例PCOS不孕女性,使用Taqman技术分析rs1764391基因多态性分布,随后评估rs1764391基因型、等位基因型对超促排卵的反应性以及ART妊娠结局的相关性.结果 PCOS患者组TT基因型、等位基因T的频率(18.4%,31.6%)显著高于正常组(9.6%,P=0.03;22.3%,P=0.04);LH浓度、窦卵泡数、hCG注射日雌激素水平、获卵数在基因型为TT的PCOS患者中要显著高于其它基因型(P<0.05);此外,受精率在不同的rs1764391基因型间无统计学差异,而TT基因型患者的种植率(27.5%)与临床妊娠率(30.7%)显著低于CC、CT基因型患者(47.2%,52.3%,P=0.02;57.4%,69.6%,P=0.03);等位基因型T患者的临床妊娠率(45.1%)均显著低于C等位基因型(66.8%,P=0.04).结论 在PCOS不孕患者中Cx37 rs1764391基因多态性与ART结局密切相关.
    • 罗卓野; 杨爱敏; 崔娜; 郝桂敏
    • 摘要: 在辅助生殖技术(ART)中,通常认为内膜厚度≤7 mm可称为薄型子宫内膜,约占体外受精周期的2.4%,其显著降低临床妊娠率.薄型子宫内膜病因以宫腔操作和炎症最多见,另有部分病因以及机制尚不明了.目前,治疗薄型内膜的方法众多,但尚无公认确切有效的治疗方法.本文主要以激素相关治疗、改善血流灌注治疗、促进内膜增殖和再生治疗等为分类,详细介绍治疗方法、分析其作用机制、评价其效果及前景,对治疗方法的最新研究进展加以总结,旨在为临床治疗薄型内膜提供思路和启示.%The endometrial thickness of ≤ 7 mm is considered thin endometrium in assisted reproductive technology (ART). Thin endometrium occurs in 2.4% of the in vitro fertilization cycles and it is linked to a lower probability of pregnancy. The most common cause of thin endometrium lies in inflammatory and iatrogenic. And some of the causes remain unknown. It has numerous treatments, but so far none of them has been widely accepted. Treatments are classified into hormone related therapy, improving blood flow therapy, improving endometrium proliferation therapy and so on. And the detail methods, mechanism and effects of the treatments were presented. This review starts from mechanism and summarizes the research advances in treatments of thin endometrium, aiming to provide new ideas to treat thin endometrium.
    • 肖楠; 张云山
    • 摘要: 辅助生殖技术(assisted reproductive technology,ART)与围产期不良妊娠结局如多胎妊娠、早产、低体质量出生、遗传印记紊乱等密切相关,而上述不良妊娠结局同样是自闭症谱系障碍(autistic spectrum disorder,ASD)发病的危险因素.关于ART与后代ASD发病率之间是否存在关联一直饱受争议,尚无定论.本文对既往观察性研究及系统评价进行综述,以期对两者之间的关系展开初探,为评估A RT技术是否对后代长期的神经心理发育造成影响奠定基础.
    • 贾青鸽; 陈书强; 郭翔宇; 董杰; 王鑫; 王晓红
    • 摘要: Objective To study the effect of assisted reproductive technology (ART) on the protein expression of amino acid transport channel in placenta.Methods We chose the placenta tissue of mice by in vitro fertilization (IVF) in 18.5 d (IVF group) and by natural pregnancy in 18.5 d (control group) to compare the birth weight,placental relative weight and ratio of the fetal/placental weight.We then detected the mRNA and protein expressions of placental amino acid transporter (Snat1,Snat2,Snat4,Latl and Lat2) by realtime quantitative polymerase chain reaction (RT-qPCR) and Western blotting.Results 1) There were no statistical differences in new birth weight between IVF group [(1 609.14± 128.23) mg] and control group [(1 640.20± 148.13) mg] (P>0.05).Compared with control group [(126.20±21.50) mg,(13.38±2.73)%],the placenta relative weight of mice was significantly higher in IVF group [(192.86±28.87) mg,P=0.000] and ratio of the fetal/placental weight was significantly lower in IVF group [(8.52 ± 1.54)%] (P=0.000).2) Compared with control group,the mRNA and protein expression of A system amino acid transporter Snatl,Snat2 and Snat4 in placenta were significantly down-regulated in IVF group (mRNA:P=0.000,P=0.008,P=0.005;protein:P=0.008,P=0.006,P=0.000).3) There were no statistical differences of the mRNA and protein expression of L system amino acid transporter Latl between these two groups (P>0.05),but the mRNA and protein expression of amino acid transporter Lat2 in placenta was significantly down-regulated in IVF group (P=0.011,P=0.000).Conclusion ART leads to the expressions of amino acid transporter Snatl,Snat2,Snat4 and Lat2 significantly down-regulated in placenta,which suggests that ART may affect the function of placenta amino acid transporter during the late pregnancy.%目的 探讨辅助生殖技术(ART)对胎盘氨基酸转运通道载体蛋白表达水平的影响.方法 分别选取体外受精(IVF)18.5 d昆明仔鼠胎盘组织(IVF组)和自然妊娠18.5 d昆明仔鼠的胎盘组织(对照组),对两组出生体质量、胎盘相对重量及胎盘效率(出生体质量与胎盘相对重量比值)进行比较和统计分析,采用实时定量聚合酶链反应(RT-qPCR)及蛋白质印迹(Western blotting)方法检测两组胎盘组织中氨基酸转运体A系统(Snat1、Snat2、Snat4)及L系统(Lat1、Lat2)的mRNA和蛋白表达水平.结果 ①IVF组新生仔鼠体质量[(1 609.14±128.23) mg]与对照组[(1 640.20±148.13) mg]间差异无统计学意义(P>0.05);IVF组小鼠胎盘相对重量[(192.86±28.87) mg]显著高于对照组[(126.20±21.50) mg](P=.000);IVF组小鼠胎盘效率[(8.52±1.54)%]显著低于对照组胎盘效率[(13.38±2.73)%](P=0.000).②与对照组相比,IVF组A系统氨基酸转运体Snat1、Snat2、Snat4mRNA和其蛋白表达水平显著下调(mRNA:P=0.000、P=0.008、P=0.005;蛋白:P=0.008、P=0.006、P=0.000).③与对照组相比,IVF组L系统氨基酸转运体Lat1 mRNA和蛋白表达水平差异无统计学意义(P>0.05);Lat2 mRNA和蛋白表达水平显著下调(P=0.011、P=0.000). 结论 ART导致小鼠足月胎盘氨基酸转运体Snat1、Snat2、Snat4及Lat2的表达水平显著下调,提示ART会影响妊娠末期胎盘氨基酸的转运能力.
    • 罗熙; 武泽; 高梦莹; 邓莲; 李永刚
    • 摘要: 我国不孕不育夫妇呈逐年上升的趋势,而辅助生殖技术(assisted reproductive technology,ART)已成为治疗不孕不育的主要方法之一.胰岛素样生长因子(IGF)2/H19基因在配子形成、受精过程、胚胎的早期发育中有着至关重要的作用,而IGF2/H19基因甲基化水平的变化直接影响其基因的表达.ART过程是否会改变IGF2/H19基因甲基化水平,这些基因甲基化水平的改变又是否会影响ART治疗后的妊娠结局.本文就这些问题结合目前的研究现状进行综述.
    • 廉颖; 刘平; 乔杰
    • 摘要: 人类辅助生殖技术(ART)实验室是ART实施的核心部门.体外受精-胚胎移植(IVF-ET)是一个复杂的操作过程,包括多项技术的实施,其工作质量直接关系到辅助生殖治疗的成败,因此,建立完善的质量控制体系、保证ART实验室的工作质量尤为重要.ART实验室的工作质量受到多方面因素的影响,包括环境、仪器设备、耗材试剂、人员及体外操作等.建立完善的ATR实验室质量控制体系,对影响实验室工作质量的诸多因素进行控制、监测和改进,有利于保证实验室工作质量的一致性和稳定性,有助于问题的及时发现和持续改进,从而进一步优化临床治疗结局.
    • 张婷; 洪燕; 申琳; 孙赟; 姚宁
    • 摘要: 目的 探讨不同受精方式对临床早期自然流产组织的染色体异常分布的影响.方法 回顾性分析102例早期流产患者的临床资料,应用微阵列比较基因组杂交技术(array-based comparative genomic hybridization,aCGH)比较体外受精(IVF)组(35例)、卵胞质内单精子注射(ICSI)组(31例)、对照组(自然妊娠及夫精人工授精组,36例)流产组织染色体异常率及拷贝数变异(copy number variants,CNVs).结果 流产组织染色体异常率3组间比较差异无显著统计学意义,其中三倍体最常见,其次为微重复/微缺失、单体等.IVF/ICSI微刺激促排卵患者流产组织核型异常比例最高,随着流产次数增加,正常核型胚胎比例增加.共检测出20个CNVs,9个CNVs为基因组微重复,11个CNVs为基因组微缺失.结论 不同受精方式不影响其自然流产妊娠物染色体异常率及异常分布,有意义的CNVs及其包含的流产相关候选基因将为进一步揭示自然流产原因提供研究方向.
    • 蔡令波; 黄洁; 刘嘉茵
    • 摘要: 近年来,辅助生殖技术(assisted reproductive technology,ART)在生殖中心应用日趋广泛,而与ART有关的医疗安全问题也日益凸显.因此有必要建立ART安全核查管理制度和操作流程,以保障ART安全,降低潜在风险,提高医护服务质量.本文结合本院生殖中心的实践情况,进行了以下3个方面的探索.首先,建立身份识别制度.在核对证件的同时,采集不孕夫妇双方的指纹和头像存档.在进行获取配子(卵子和精子)前、胚胎移植前和冷冻胚胎复苏周期胚胎移植前均通过指纹系统进行身份验证.其次,建立医疗档案管理制度,实现辅助生殖病案的信息化管理.最后,建立严格的核查制度,包括检验查对、用药查对、手术安全核查、胚胎实验室安全核查等制度.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号